Sugi Predict

Sugi Predict / Compounds / SCHEMBL3384005

SCHEMBL3384005

SCHEMBL3384005

CC(C)(C)OC(=O)NC1CCN(c2ccc([N+](=O)[O-])c(N)c2)C1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.48
▸ SIRT6 Q8N6T7 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ RECQL P46063 1/20 0.46
▸ SUV39H2 Q9H5I1 8/20 0.45
▸ HDAC3 O15379 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ DRD2 P14416 1/20 0.43
▸ MAP4K4 O95819 2/20 0.42
▸ PIM1 P11309 1/20 0.42
▸ PIM3 Q86V86 1/20 0.42
▸ PIM2 Q9P1W9 1/20 0.42
▸ CTSK P43235 2/20 0.42
▸ BTK Q06187 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14892233 0.94 LMNA (0.53) MAPTSIRT6LMNARECQLSUV39H2
SCHEMBL31331951 0.92 DRD2 (0.45) MAPTLMNASUV39H2HDAC3HDAC1
SCHEMBL31331790 0.92 DRD2 (0.45) MAPTLMNASUV39H2HDAC3HDAC1
SCHEMBL7235706 0.89 HPGD (0.48) MAPTLMNASUV39H2DRD2PIM1
SCHEMBL4253922 0.88 SUV39H2 (0.45) SUV39H2DRD2PIM1PIM3PIM2
SCHEMBL2578938 0.88 SUV39H2 (0.46) SUV39H2DRD2PIM1PIM3PIM2
SCHEMBL15093029 0.88 SUV39H2 (0.46) SUV39H2DRD2PIM1PIM3PIM2
SCHEMBL4253928 0.88 SUV39H2 (0.45) SUV39H2DRD2PIM1PIM3PIM2
SCHEMBL31332026 0.86 MAP4K4 (0.49) MAPTLMNASUV39H2HDAC3HDAC1
SCHEMBL7235725 0.84 SUV39H2 (0.48) SUV39H2HDAC3HDAC1HDAC2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2573079-A2 Benzimidazole quinolinones and uses thereof Novartis Vaccines and Diagnostics, Inc. (US) 2013-03-27 — — EP disclosed
EP-1497287-B1 Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-11-24 — — EP disclosed
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 — — US disclosed
US-20100184754-A1 QUINOLINONE DERIVATIVES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2010-07-22 — — US disclosed
US-20090281100-A1 Benzimidazole quinolinones and uses thereof BARSANTI PAUL A 2009-11-12 — — US disclosed
US-7598268-B2 Quinolinone derivatives NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-10-06 — — US disclosed
EP-1539754-A4 BENZIMIDAZOLE QUINOLINONES AND USES THEREOF NOVARTIS VACCINES & DIAGNOSTIC (US) 2009-02-25 — — EP disclosed
US-7470709-B2 Benzimidazole quinolinones and uses thereof NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 — — US disclosed
US-20080070906-A1 QUINOLINONE DERIVATIVES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-03-20 — — US disclosed
US-7335774-B2 Quinolinone derivatives NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-02-26 — — US disclosed
US-20040092535-A1 Benzimidazole quinolinones and uses thereof CHIRON CORPORATION 2004-05-13 — — US disclosed
WO-2004018419-A2 BENZIMIDAZOLE QUINOLINONES AND USES THEREOF CHIRON CORPORATION (US) 2004-03-04 — — WO disclosed
US-20040006101-A1 Quinolinone derivatives CHIRON CORPORATION 2004-01-08 — — US disclosed
WO-2003087095-A1 QUINOLINONE DERIVATIVES CHIRON CORPORATION (US) 2003-10-23 — — WO disclosed
US-20030158224-A1 Quinolinone derivatives CHIRON CORPORATION 2003-08-21 — — US disclosed
US-6605617-B2 Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase CHIRON CORPORATION 2003-08-12 — — US disclosed
EP-1317442-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-06-11 — — EP disclosed
US-20030028018-A1 Quinolinone derivatives CHIRON COPORATION 2003-02-06 — — US disclosed
US-20020107392-A1 Quinolinone derivatives NOVARTIS AG (CH) 2002-08-08 — — US disclosed
WO-2002022598-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070906-A1 QUINOLINONE DERIVATIVES SLCO1B1, SLCO1B3, SLCO1A2 MAPT 1907/4885SIRT6 2150/4885LMNA 2596/4885
US-20090281100-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 MAPT 575/4885SIRT6 2248/4885LMNA 1957/4885
US-20030028018-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 MAPT 2067/4885SIRT6 2160/4885LMNA 2734/4885
US-20030158224-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 MAPT 2067/4885SIRT6 2160/4885LMNA 2734/4885
US-20020107392-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 MAPT 2067/4885SIRT6 2160/4885LMNA 2734/4885
US-20100184754-A1 QUINOLINONE DERIVATIVES SLCO1B1, SLCO1B3, SLCO1A2 MAPT 1907/4885SIRT6 2150/4885LMNA 2596/4885
US-20040092535-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 MAPT 711/4885SIRT6 2289/4885LMNA 2053/4885
US-20040006101-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 MAPT 2067/4885SIRT6 2160/4885LMNA 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.